alexa Mousemodel For Testing Anti-Dux4 Therapies For FSHD | 22369
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Cell & Gene Therapy

Abhijit Dandapat, Robert Arpke, Darko Bosnakovski, Lynn Hartweck, Kristen A Baltgalvis, Derek Vang, Megan Roth, June Baik, Radbod Darabi, Rita C R Perlingeiro, Dawn A Lowe, Kent Hamra, Kalpna Gupta and Michael Kyba
Accepted Abstracts: J Stem Cell Res Ther
DOI: 10.4172/2157-7633.S1.009
Abstract
(FSHD) patients typically suffer from asymmetric muscle loss with age and the disease is associated with genomic alterations that lead to dominant expression of the toxic DUX4 protein. To generate an animal model to study the effects of DUX4, a doxycycline-inducible transgene encoding DUX4 and 3? genomic DNA was introduced into a euchromatic region of the mouse X chromosome. Surprisingly, without induction, DUX4 RNA was expressed at low levels in many tissues and animals displayed a variety of unexpected dominant leaky phenotypes, including male-specific lethality. Occasional live-born males were expressed DUX4 RNA at low levels but did not show signs of dystrophy before they died by 4-6 weeks of age. To study the effects of DUX4 expression on muscle regeneration, this lethality was bypassed by isolating and transplanting iDUX4 satellite cells from iDUX4 males. In the presence of doxycycline, it was observed a dose-dependent suppression of new fiber formation by transplanted satellite cells. Data on the use of this conditional model to test anti-DUX4 therapeutics, specifically gene therapy targeting the DUX4 message in transplanted satellite cells will be presented. This approach, using the first transgenic mouse model to show pathologies due to FSHD-related D4Z4 sequences, allows quantitative testing of therapies for FSHD directed against DUX4.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version